Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
2023-505638-82-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of crovalimab in atypical hemolytic uremic syndrome (aHUS), sponsored by Roche. Primary endpoint: Proportion of patients with complete TMA response (cTMAr) anytime from baseline to Week 25. Planned start Feb 2024; status: authorised.
02
Drugs
crovalimab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2023-505638-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505638-82-00.